Study to Evaluate Safety, Dose Response and Immunogenicity of the Measles Vaccine MVA mBN85B in Healthy Children Aged 6 Months to 6 Years

NCT00891007 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Measles

Interventions

BIOLOGICAL: MVA-mBN85B
BIOLOGICAL: MVA-mBN85B
BIOLOGICAL: Rouvax

Sponsor

Bavarian Nordic